Is Tirzepatide Safe? Side Effects, Contraindications, What Clinicians Monitor

Key takeaways

Tirzepatide's common side effects are gastrointestinal and dose-related: in the pooled Zepbound trials, nausea affected 25 to 29 percent versus 8 percent on placebo, diarrhea 19 to 23 versus 8, vomiting 8 to 13 versus 2 and constipation 11 to 17 versus 5; 4.8 to 6.7 percent stopped for side effects, against 3.4 percent.
Serious risks are uncommon but real: pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia with insulin or sulfonylureas, severe allergic reactions, and a boxed thyroid warning that makes a personal or family history of medullary thyroid carcinoma or MEN 2 a contraindication.
The suicidal behavior and ideation warning came off the Zepbound label in February 2026 after FDA's review found no increased risk; large cohort studies agree. Clinicians still ask about mood.
Oral contraceptives may absorb less reliably: add a barrier method for four weeks after starting and after each dose increase. Tell every surgeon and anesthesiologist you take it. Stop it when a pregnancy is recognized.
A compounded vial adds risks a pen does not have: unverified content and dosing errors, which is where FDA's adverse-event reports point.

Tirzepatide is about as safe as its label says, and the label is detailed. In the trials behind Mounjaro, Zepbound and every compounded tirzepatide vial, most side effects were gastrointestinal, mild to moderate and concentrated in the dose-escalation weeks, which is why the four-week steps in the tirzepatide dosage chart matter. The serious risks are rare and specific; here they are in the label's own numbers.

Side effects by dose: the label's numbers

The table is from the pooled placebo-controlled weight-management trials on the label (2,519 people treated for up to 72 weeks): reactions in at least 2 percent of tirzepatide users and more common than on placebo (Zepbound label).

Adverse reaction	Placebo (N=958)	5 mg (N=630)	10 mg (N=948)	15 mg (N=941)
Nausea	8%	25%	29%	28%
Diarrhea	8%	19%	21%	23%
Vomiting	2%	8%	11%	13%
Constipation	5%	17%	14%	11%
Abdominal pain	5%	9%	9%	10%
Dyspepsia (indigestion)	4%	9%	9%	10%
Injection-site reactions	2%	6%	8%	8%
Fatigue	3%	5%	6%	7%
Hypersensitivity reactions	3%	5%	5%	5%
Hair loss	1%	5%	4%	5%
Gastroesophageal reflux	2%	4%	4%	5%

Some gastrointestinal reaction occurred in 56 percent of users at every dose, against 30 percent on placebo; severe ones in 1.7, 2.5 and 3.1 percent (5, 10 and 15 mg) against 1 percent; and 4.8, 6.3 and 6.7 percent stopped permanently because of adverse reactions, against 3.4 percent, mostly in the first months. Most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time. Hair loss tracked the weight reduction and affected 7.1 percent of women versus 0.5 percent of men; hypotension occurred in 1.6 versus 0.1 percent, and hypersensitivity reactions were mostly rash and itching (Zepbound label).

The boxed warning: thyroid C-cell tumors

In rats, tirzepatide caused thyroid C-cell tumors, including carcinomas, in a dose- and duration-dependent way at exposures similar to human use; whether it does the same in people is unknown. On that basis the label contraindicates it in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and tells patients to report a neck mass, difficulty swallowing, shortness of breath or persistent hoarseness. Routine calcitonin tests or thyroid ultrasound are described as of uncertain value and liable to cause unnecessary procedures (Zepbound label). Every GLP-1 receptor agonist carries the same warning.

The serious risks on the label

Pancreatitis. Acute pancreatitis, including fatal hemorrhagic and necrotizing cases, has been seen with GLP-1 receptor agonists and with tirzepatide. In the pooled weight-management trials, adjudicated pancreatitis occurred in 0.2 percent on tirzepatide and 0.2 percent on placebo; in the diabetes trials the rate was 0.23 versus 0.11 per 100 patient-years. Persistent or severe abdominal pain, sometimes radiating to the back, means stop and be evaluated; amylase and lipase rise 20 to 35 percent on average even without pancreatitis.

Gallbladder disease. Cholecystitis occurred in 0.7 percent on tirzepatide versus 0.2 percent on placebo and cholecystectomy in 0.2 percent versus none; gallstones were about equal (1.1 versus 1 percent), and the label ties the events to the weight loss itself. A meta-analysis of 76 randomized trials of GLP-1 receptor agonists (103,371 people) found a 37 percent relative increase in gallbladder or biliary disease, more than doubling in weight-loss trials and rising with dose and duration (He 2022); that is class data, not tirzepatide-specific.

Hypoglycemia with insulin or sulfonylureas. In the diabetes weight-management trial, blood glucose under 54 mg/dL occurred in 4.2 percent on tirzepatide versus 1.3 percent on placebo, and in 10.3 percent of those also taking a sulfonylurea versus 2.1 percent of those not. The label says to consider lowering the insulin or sulfonylurea dose when starting, to monitor glucose in diabetes, and to teach everyone the symptoms; without diabetes, glucose under 54 mg/dL was recorded in 0.3 percent.

Acute kidney injury from dehydration. Post-marketing reports include kidney injury, some needing dialysis, mostly after nausea, vomiting or diarrhea led to dehydration; in the trials it was reported in 0.5 versus 0.2 percent. The label asks clinicians to monitor kidney function in anyone with fluid-losing side effects, especially during escalation.

Severe gastrointestinal disease and retinopathy. The drug is not recommended in severe gastroparesis, and post-marketing reports include ileus, intestinal obstruction and fecal impaction. Rapid improvement in glucose control can temporarily worsen diabetic retinopathy, so people with type 2 diabetes and retinopathy should be monitored for progression.

Hypersensitivity. Anaphylaxis and angioedema have been reported after approval; severe reactions occurred in 0.1 percent of trial participants versus none on placebo. A previous serious reaction to tirzepatide is a contraindication, and a reaction to another GLP-1 drug calls for caution (Zepbound label).

Suicidal ideation: what changed in 2026

FDA's January 2024 preliminary evaluation found no evidence that these drugs cause suicidal thoughts or actions, and on January 13, 2026 FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the suicidal behavior and ideation warning after a pooled review of placebo-controlled trials found no increased risk (Psychiatric Times 2026); the Zepbound label records the warning as removed in February 2026 (Zepbound label). Cohort data agree: in Swedish and Danish registers, 124,517 adults starting a GLP-1 receptor agonist had no higher rate of suicide death than 174,036 starting an SGLT2 inhibitor (Ueda 2024). Those were mostly people with diabetes, so the question is less settled in weight management and in people with a psychiatric history; clinicians still ask about mood, and anyone with new depression or suicidal thoughts should say so.

Surgery and anesthesia

Tirzepatide slows stomach emptying, and there have been rare post-marketing reports of pulmonary aspiration under general anesthesia or deep sedation in people on GLP-1 receptor agonists who had fasted as instructed. The label says the data are insufficient to say whether holding the drug or changing fasting rules helps, and tells patients to inform their providers before any surgery or procedure (Zepbound label).

The anesthesia societies have gone further. On June 29, 2023, the American Society of Anesthesiologists issued consensus guidance to consider holding weekly GLP-1 agonists for a week before elective procedures, delaying the case if gastrointestinal symptoms are present, and treating anyone who did not hold the drug as having a full stomach, noting that the basis was anecdotal reports (ASA 2023). In October 2024 five societies, including the ASA, replaced the blanket hold with a risk-based approach: most people continue the drug up to the day of surgery, while those at higher risk of delayed emptying (still escalating, on higher doses, with gastrointestinal symptoms, or with conditions such as gastroparesis) take only liquids for 24 hours beforehand (Kindel 2024). The practical rule is unchanged: tell the team, and let them decide.

Oral contraceptives and other oral medicines

Because it slows stomach emptying, tirzepatide can change how oral drugs are absorbed. The label singles out oral hormonal contraceptives: people using the pill are told to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase; patches, rings, implants, injections and IUDs are unaffected. Narrow-therapeutic-window drugs such as warfarin should be monitored, and tirzepatide should not be combined with any other GLP-1 receptor agonist (Zepbound label).

Pregnancy and breastfeeding

Weight loss offers no benefit in pregnancy and may cause fetal harm; the label says to stop tirzepatide when a pregnancy is recognized. Human data are too few to measure the risk of birth defects or miscarriage; in animal studies fetal growth reductions and malformations occurred at clinically relevant exposures. In a single-dose study in 11 breastfeeding women, tirzepatide was undetectable in nearly all milk samples; effects on an infant have not been studied (Zepbound label).

What clinicians monitor

The label sets no lab schedule but says what to watch:

Before starting: personal and family thyroid cancer history, MEN 2, prior pancreatitis, gallbladder disease, gastroparesis, diabetic retinopathy, insulin or sulfonylurea use, pregnancy plans and contraception, kidney function, and mood.
During escalation: tolerance of each step; hydration and kidney function when there is vomiting or diarrhea; glucose in diabetes; blood pressure in people on antihypertensives, since hypotension and dizziness were more common on the drug.
Ongoing: weight, mood, any new abdominal pain, and a conversation before any procedure requiring sedation.
Not routinely: calcitonin or thyroid ultrasound, which the label calls of uncertain value, and amylase or lipase in someone without symptoms.

When to seek care

The same day, or the emergency department: severe or persistent abdominal pain, especially radiating to the back (pancreatitis); pain under the right ribs with fever or jaundice (gallbladder); vomiting that prevents keeping fluids down, or markedly reduced urination (dehydration and kidney injury); swelling of the face, lips, tongue or throat, or difficulty breathing (anaphylaxis or angioedema); severe constipation with abdominal distension and vomiting (obstruction); confusion, sweating or shakiness in someone on insulin or a sulfonylurea (hypoglycemia); and suicidal thoughts. Within days: a new neck lump, hoarseness or trouble swallowing; a positive pregnancy test; or side effects that do not ease after a dose step.

The added risks of compounded versions

Everything above applies to the molecule. A compounded vial adds risks that belong to the product: no one tests the vial for potency or sterility, and the dose must be drawn in syringe units from the concentration on the label. FDA has received reports of overdoses from dosing errors with compounded injectable GLP-1 products, some requiring hospitalization, and had logged hundreds of adverse-event reports for compounded tirzepatide by mid-2026, while cautioning that reports do not establish causation and probably undercount (FDA GLP-1 concerns page). In FDA's adverse-event reporting system for 2018 to 2024, reports involving compounded GLP-1 products had 49 times the odds of a preparation error, 19 times the odds of contamination and 2.4 times the odds of hospitalization compared with reports on approved products, although reporting data cannot prove cause (McCall 2026). The compounded tirzepatide hub covers the dosing arithmetic and the legal limits; the legal tracker has the dates.

Bottom line

Tirzepatide is a well-characterized drug with a predictable side-effect profile: expect nausea and bowel changes during escalation, know the serious warning signs, and do not take it with a personal or family history of medullary thyroid cancer, in pregnancy, or with insulin and sulfonylureas without a dose plan. The least safe thing about tirzepatide in 2026 is not the molecule but an unverified vial and a units calculation done wrong.

Frequently asked questions

+Is tirzepatide safe to take long term?

The longest controlled data are three years: in the SURMOUNT-1 extension, 1,032 adults with obesity and prediabetes took tirzepatide or placebo for 176 weeks, the most common adverse events were gastrointestinal and concentrated in the first 20 weeks of dose escalation, and the investigators reported no new safety signals. What three years cannot answer is lifetime risk, including the thyroid question, which is why the boxed warning remains and why the drug is contraindicated with a personal or family history of medullary thyroid carcinoma.

+Does tirzepatide cause hair loss?

Hair loss was reported by 4 to 5 percent of people on Zepbound in the pooled trials, against 1 percent on placebo. The label attributes it to the weight reduction itself rather than a direct drug effect, and it was far more common in women (7.1 percent) than men (0.5 percent). No participant stopped the drug because of it. Rapid weight loss from any cause can trigger a temporary shedding that usually settles over months.

+How long does tirzepatide nausea last?

In the trials, most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time; the label's four-week minimum between steps exists for that reason. If a step is not tolerated, the label allows staying longer at the current dose or settling at a lower maintenance dose. Nausea that is persistent, severe, or accompanied by abdominal pain radiating to the back or by an inability to keep fluids down is not ordinary escalation nausea and needs a clinician the same day.

+Is compounded tirzepatide safe?

The drug is the same; the product is not. A compounded vial has no FDA review of its potency or sterility, and the dose must be drawn in syringe units from a concentration on the label, which is where the documented overdoses have come from. FDA has logged hundreds of adverse-event reports for compounded tirzepatide, and an analysis of its reporting database found reports involving compounded GLP-1 products had far higher odds of preparation errors, contamination and hospitalization than reports involving approved products. A compounded vial from a licensed, named pharmacy is still a different thing from a research vial bought online.

+What does tirzepatide do to your body?

It activates the receptors for two gut hormones, GIP and GLP-1. The result is more insulin when blood sugar is high, less glucagon, slower stomach emptying and less appetite, so people eat less and lose weight; blood pressure, lipids and glucose improve with the weight. The same slowing of the stomach causes the nausea, reflux and constipation, and can change how oral medicines are absorbed. Heart rate rises by one to three beats per minute on average.

+Does tirzepatide cause thyroid cancer?

In rats, tirzepatide caused thyroid C-cell tumors at clinically relevant exposures, which is the basis of the boxed warning. Whether it does so in humans is unknown; the human relevance of the rodent finding has not been determined. Because of that uncertainty the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2, and the label tells patients to report a neck mass, trouble swallowing, shortness of breath or persistent hoarseness.

+Should I stop tirzepatide before surgery?

Tell the surgeon and anesthesiologist, and let them decide. Tirzepatide slows stomach emptying, and there have been rare reports of aspiration under general anesthesia despite normal fasting. The American Society of Anesthesiologists suggested in June 2023 holding weekly GLP-1 drugs for a week before elective procedures; its October 2024 multisociety guidance moved to a risk-based approach in which most people continue the drug and those at higher risk (still escalating, on higher doses, or with gastrointestinal symptoms) follow a liquid diet for 24 hours beforehand. The label says the data are not yet sufficient to settle the question.

+Can I take tirzepatide with birth control pills?

Yes, with a precaution. Delayed stomach emptying may reduce how reliably oral hormonal contraceptives are absorbed, most of all after the first dose. The label tells people on oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. Patches, rings, implants, injections and IUDs are not affected.